Insurance Status Contributes to Racial Disparities in Breast Cancer

A new study reports that a lack of adequate health insurance is responsible for nearly half of racial and ethnic disparities in breast cancer stage at diagnosis.Earlier detection and treatment of breast cancer can significantly improve outcomes for patients diagnosed with this disease. However, studies have shown that a higher proportion of women of racial and ethnic minorities present with breast cancer at more advanced stages, negatively impacting their treatment and prognosis. In a study now ...
Continue reading

Antioxidant Supplements Worsen Breast Cancer Outcomes

An analysis of a phase 3 trial found that taking antioxidants and other dietary supplements during chemotherapy can decrease survival and increase the risk of recurrence in patients with breast cancer.Antioxidants such as vitamins A, C, and E, carotenoids, and coenzyme Q10 occur naturally in fruits, vegetables, and whole grains, but many patients with cancer take additional vitamins and minerals to supplement their diets while undergoing treatment. However, recent research has shown that antioxi...
Continue reading

New FDA Approval for Relapsed/Refractory HER2-Positive Metastatic Breast Cancer

​The FDA has now granted accelerated approval to fam-trastuzumab deruxtecan-nxki (Enhertu®, Daiichi Sankyo) for patients with unresectable or metastatic human epidermal growth factor receptor 2 (HER2)-positive breast cancer previously treated with at least two anti-HER2–based regimens in the metastatic setting. Fam-trastuzumab deruxtecan-nxki, otherwise known as trastuzumab deruxtecan, is an antibody-drug conjugate consisting of an anti-HER2 antibody, a cleavable tetrapeptide-based linker, and a...
Continue reading

What Are the Most Common Causes of Death for Breast Cancer Survivors?

Researchers discovered that a significant number of breast cancer survivors die from heart and cerebrovascular diseases, providing important insight on how breast cancer survivors should be counseled on potential health risks. In this study, published in Cancer, data on 754,270 women who were diagnosed with breast cancer during 2000 through 2015 from the Surveillance, Epidemiology, and End Results (SEER) program were analyzed. The researchers then calculated standardized mortality ratios for cau...
Continue reading

Anastrozole Effective at Reducing Long-Term Breast Cancer Risk

Tamoxifen has been known to be an effective drug to reduce risk of breast cancer in high-risk women. Another drug, anastrozole, an aromatase inhibitor that decreases the amount of estrogen the body produces, has been shown in the IBIS-II trial to also reduce the risk of breast cancer in high-risk women during the five-year treatment. Anastrozole has fewer long-term side effects than tamoxifen; however, does anastrozole protect women past the five-year treatment completion? Researchers continued ...
Continue reading

Copyright © 2020 i3 Health. All rights reserved.